BILBF yields 370.37% · PFE yields 6.20%● Live data
📍 BILBF pulled ahead of the other in Year 1
Combined, BILBF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BILBF + PFE for your $10,000?
Kinovo plc, through its subsidiaries, provides gas heating, electrical, and general building services to housing associations and local authorities, public buildings, industrial and commercial, and education and private sectors in the United Kingdom. The company operates through Mechanical Services, Building Services, and Electrical Services segments. It offers safety and regulatory compliance services for electric, gas, access control systems, ventilation and fire alarm systems, and water hygiene services; and home and community regeneration services, including new home construction, brownfield site regeneration, vacant building conversion, habitual spaces improvement, building maintenance, reactive repairs and maintenance, create greener buildings, disabled adaption work, unused space reutilization, and kitchen and bathroom installations. The company also delivers and installs photovoltaic solar microgeneration systems, ground and air source heat pumps, electric vehicle charging, air source heat pumps, energy boilers and lightings, and energy management systems. In addition, it provides meter connections and central heating installation solutions; window installations, and painting and decorating services; servicing, maintenance, emergency call out, and rewiring solutions. The company was formerly known as Bilby Plc and changed its name to Kinovo plc in June 2021. Kinovo plc was incorporated in 2014 and is based in London, the United Kingdom.
Full BILBF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.